Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae
Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae
复制标题
DOI：
10.1128/aac.47.10.3343-3344.2003
复制
发表时间：
2003-10-01
影响因子：
4.9
通讯作者：
Edwards, JE
中科院分区：
文献类型：
--
作者：
Ibrahim, AS;Avanessian, V;Edwards, JE
在血源性播散性根霉感染的糖尿病小鼠模型中，比较脂质体阿替霉素B（LAm B）和阿替霉素B脱氧胆酸盐（Am B）的疗效。以7.5 mg/kg体重，每日两次（b.i.d.）给药，与未处理的对照小鼠（P = 0.001）和用0.5 mg AmB/kg b.i.d.处理的小鼠的存活率相比，LAmB显著改善了总存活率。（P = 0.047）。这些数据表明，高剂量LAmB比AmB更有效地治疗小鼠播散性真菌病。
The efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB) were compared in a diabetic murine model of hematogenously disseminated Rhizopus oryzae infection. At 7.5 mg/kg of body weight twice a day (b.i.d.), LAmB significantly improved overall survival compared to the rates of survival in both untreated control mice (P = 0.001) and mice treated with 0.5 mg of AmB per kg b.i.d. (P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.